Another factor influencing the rating is the uncertainty surrounding Novavax’s pipeline developments, particularly the phase 3 CIC program, which has faced delays due to a clinical hold by the FDA.

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Our Second Value Driver is Novavax's late-stage pipeline. Our late-stage pipeline is comprised of our COVID-19 influenza ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Novavax also said during its latest earnings report that it would unveil an "expanded clinical pipeline" by year-end. So, what does all this mean for investors? Novavax remains in a period of ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday ... The company will, meanwhile, focus on its early pipeline of ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...